Medicare Compliance & Reimbursement
Dramatic Payment Drops Set For Common Drugs
Even though the Centers for Medicare and Medicaid Services has been collecting information from physicians who say they can't obtain drugs at the rock-bottom prices Medicare has been paying, the newest numbers don't show much improvement for payments.
CMS released the latest drug rates, based on 106 percent of Average Sales Price data, and many chemotherapy drugs were treated to sharp decreases.
The hardest hit include Cytarabine, which dropped around 38 percent; Etoposide, which dropped around 33 percent; and Carboplatin injection, which fell to around
31 percent.
CMS insisted that it didn't hit the highest-volume drug codes hard. For 20 out of the top 40 most common drugs, payment amounts changed 2 percent or less. And for 18 out of the 40 highest-volume drugs, payment amounts actually increased, CMS says. But the average amount Medicare pays for all drugs will decrease by 2 percent in July, and so will the average payment for the top physician-administered drugs.
"The decrease in so many of the drugs that oncology practices use will be huge for several practices," says Carolyn Davis, director of reimbursement with Oncology Hematology West in Papillion, NE.
Smaller practices that can't take advantage of volume purchasing rebates will have an especially hard time with these new rates. Davis says Oncology Hematology West will be looking at its drug regimens in the light of these new numbers.
Medicare Compliance & Reimbursement
- MEDICARE DRUG BENEFIT:
CMS Demanding Extensive Formularies From PDPs
Some sponsors say government going back on its word.
Could the Part D drug benefit wind [...] - MEDICARE DRUG BENEFIT:
Still Plenty Of Room For Efficient PDPs To Profit
Strong step therapy program puts PDPs on payment path.
Not everyone thinks the Centers for Medicare [...] - PHYSICIANS:
AMA Won't Say 'A-OK' To Any Substandard P4P
Physicians set 'principles' that will guide P4P decisions.
Pay-For-Performance anxiety dominated the American Medical Association's House [...] - PHARMACEUTICALS:
Dramatic Payment Drops Set For Common Drugs
New rates could hit hardest in smaller offices.
Even though the Centers for Medicare and Medicaid [...] - SPECIALTY HOSPITALS:
Goodbye, Moratorium...Hello, Prohibitions
New set of restrictions parallel the just-lifted moratorium.
Just as specialty hospitals were breathing a sigh [...] - HOME HEALTH:
It's A Mistake To Hold Onto That ABN
Delayed ABNs ignore the NEMB altogether.
One of the biggest gray areas regarding the new expedited [...] - HOME HEALTH:
CMS Rolling Out Termination Notice Rule July 1
... but notices don't yet have that prime-time shine, experts protest.
Home health agencies should get [...] - HOSPITALS:
Start NPI Application Process Early
The new NPI will make life easier, but providers aren't spared the legwork.
Hospitals that feel [...] - HOSPITALS:
CMS Extends Electronic Cost-Reporting Period
Transition period still possible for providers.
Organ procurement organizations and rural health clinics must now submit [...] - ENFORCEMENT WATCH:
OIG Finds Fertile Fraud Hunting Grounds
HHS watchdog sniffs out 258 criminal actions in the first half of FY 2005.
Providers, watch [...] - HOSPITALS:
QIO Participation May Not Yield Improvements
Study finds no quality differences between participating and non-participating hospitals.
A new study suggests quality improvement [...] - BILL WATCH
The following bills were introduced in the Senate: S. 1277. A bill to amend title [...]
